-$0.24 EPS Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter
Wall Street brokerages expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce earnings per share (EPS) of ($0.24) for the current quarter, Zacks reports. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.13). Dicerna Pharmaceuticals reported earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 73.9%. The firm is scheduled to report its next earnings report on Thursday, November 1st.
Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.
In other Dicerna Pharmaceuticals news, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total value of $232,496.00. Following the completion of the sale, the director now directly owns 29,064 shares of the company’s stock, valued at approximately $465,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total transaction of $40,267.50. Following the completion of the sale, the insider now directly owns 26,781 shares of the company’s stock, valued at $468,667.50. The disclosure for this sale can be found here. Insiders own 19.85% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $102,000. Jane Street Group LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $136,000. Verition Fund Management LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $141,000. State Board of Administration of Florida Retirement System bought a new stake in Dicerna Pharmaceuticals in the 2nd quarter worth about $178,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Dicerna Pharmaceuticals in the 2nd quarter worth about $188,000. 74.47% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:DRNA traded up $0.57 during midday trading on Monday, hitting $12.33. 1,006,100 shares of the company’s stock were exchanged, compared to its average volume of 555,737. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40. The company has a market cap of $726.85 million, a PE ratio of -3.37 and a beta of 2.43. Dicerna Pharmaceuticals has a 12 month low of $4.91 and a 12 month high of $17.98.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Read More: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.